[go: up one dir, main page]

WO2000067759A1 - Inhibiteurs specifiques nouveaux agissant contre l'inflammation aiguë ou chronique - Google Patents

Inhibiteurs specifiques nouveaux agissant contre l'inflammation aiguë ou chronique Download PDF

Info

Publication number
WO2000067759A1
WO2000067759A1 PCT/SE2000/000827 SE0000827W WO0067759A1 WO 2000067759 A1 WO2000067759 A1 WO 2000067759A1 SE 0000827 W SE0000827 W SE 0000827W WO 0067759 A1 WO0067759 A1 WO 0067759A1
Authority
WO
WIPO (PCT)
Prior art keywords
uridine
cells
adhesion
neutrophils
thiouridine
Prior art date
Application number
PCT/SE2000/000827
Other languages
English (en)
Inventor
Srinivas Uppugunduri
Original Assignee
Srinivas Uppugunduri
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Srinivas Uppugunduri filed Critical Srinivas Uppugunduri
Priority to AU52592/00A priority Critical patent/AU776520B2/en
Priority to EP00937418A priority patent/EP1181021B1/fr
Priority to BR0010283-0A priority patent/BR0010283A/pt
Priority to JP2000616785A priority patent/JP2002544165A/ja
Priority to DE60035583T priority patent/DE60035583T2/de
Priority to CA002373052A priority patent/CA2373052A1/fr
Publication of WO2000067759A1 publication Critical patent/WO2000067759A1/fr
Priority to US09/986,522 priority patent/US20020061863A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Definitions

  • the present invention relates to novel, specific inhibitors of acute and chronic inflammation, method for treatment of acute and chronic inflammation and/or problems in hemostasis related to platelet function..
  • the object of the present invention is to obtain novel, specific inhibitors of acute and chronic inflammations in order to be able to treat such inflammations.
  • CAMs cell-adhesion molecules
  • selectins Three families of cell-adhesion molecules (CAMs) have been implicated in mediating interactions of platelets, endothelial cells, and leukocytes: the selectins, the integrins and the immunoglobulin superfamily.
  • the selectin family of molecules comprising E-, L-, and P- selectin act in concert with other cell adhesion molecules to effect adhesive interactions of platelets, endothelial cells, and leukocytes.
  • Extensive literature is available implicating cell adhesion molecules in diverse disease processes including reperfusion injury, cancer, coronary heart disease, atherosclerosis, restenosis after coronary angioplasty, and chronic inflammatory diseases like asthma and IBD.
  • the emigration of white blood cells to inflammatory sites requires at least four steps: leukocyte rolling along activated endothelium, leukocyte activation, firm adhesion and transendothelial migration. Interaction of the selectins with their carbohydrate ligands seems to be important for the initial binding of the leukocytes to the endothelium under conditions of fluid shear stress. Subsequent firm adhesion and extravasation seems to be mediated by another family of molecules, the ⁇ 2 (CD 18)-integrins. A number of soluble mediators like IL-l ⁇ , TNF, endotoxin, thrombin and histamine can up regulate one or more endothelial adhesion molecules.
  • the major adhesion receptors and ligands regulating leukocyte- endothelium interactions include ICAM-1, ICAM-2/LFA-1; VCAM/VLA-4; L-selectin/GlyCAM-1; CD 34, MAdCAM-1 ; E-selectin/ESL-1, PSGL-1 ; P-selectin/PSGLl
  • mice deficient in each of these selectins suggest that they provide overlapping, but crucial contributions to leukocyte recruitment in inflammation. Mice lacking each of these selectins exhibit defects in neutrophil rolling and extravasation. Further, mice deficient in both E and P selectin present extreme leukocytosis, elevated cytokine levels and alterations in haematopoesis.
  • Platelet P-selectin may also play a very important role in both hemostasis and the ensuing inflammatory reaction. Platelets are rapidly recruited to the site of the vascular injury to prevent excessive bleeding. The interaction of platelets with the vessel wall is a crucial event leading to the formation of a hemostatic plug. The role of platelet P-selectin in hemostasis was confirmed in a recent study which showed that platelets roll on stimulated endothelium expressing P-selectin in vivo. Furthermore, bleeding time was prolonged by 40% in P- selectin deficient mice.
  • Today the treatment of inflammatory conditions include treatment using steroids which ne- gatively affect the immuno defence system and leads to a total inhibition of the inflammation, where it is of interest and importance to control the inflammatory regulating system.
  • WO 96/01115 relates to pyrimidine nucleotide precursors for treatment of systemic inflammation and encompasses uridine.
  • the systemic inflammations are caused by bacterial sepsis.
  • Inflammation is a common feature in the pathogenesis of numerous diseases. Inflammation is normally localized defensive response to invasion of the host by foreign material. Inflammation can be caused by a wide variety of agents including mechanical trauma, toxins, and neoplasia and is not a response reserved exclusively for bacterial infections. The accumulation and subsequent activation of leukocytes are, however, central events in the pathogenesis of virtually all forms of inflammation.
  • L-cells permanently transfected with full-length E-selectin by electroporation.
  • Human neutrophils were isolated from EDTA whole blood by density centrifugation. Purity and total number were determined by standard haematology instruments. L-cells were grown in 96-well microtiter plates.
  • L-cells and neutrophils were pre-incubated with respective substances for 45 min at 37°C .
  • Neutrophils were then allowed to adhere to L-cells in the presence of different substances for 20 min at 37°C.
  • Non-adherent cells were removed by repeated washings and the number of adherent cells determined by measuring myeloperoxidase content. Since binding of neutrophils to selectin is calcium dependent, EGTA (which chelates calcium) was used as a negative control.
  • Endothelial cells were grown in 96-well microtiter plates to confluence. They were stimulated with T ⁇ F for 4 h at 37°C. Isolated neutrophils were incubated for 30 min at 37°C with respective substances. The endothelial cells were washed after 4 h and 2 x 10 5 neutrophils were added to each well and the cells were allowed to adhere in the presence of the respective substances. Isomaltitol inhibited the adhesion of neutrophils to TNF stimulated HUVEC by roughly 30%. Once again a clear dose-response was not observed. In fact, the opposite seems to be true with increasing inhibition with decreasing dose (Fig 7).
  • 4-Thiouridine was more potent in inhibiting adhesion of neutrophils to TNF stimulated HUVEC. 4-Thiouridine reduced the adhesion of neutrophils by 60 %. Maximal adhesion seemed to occur already in the micromolar levels.
  • Fig 8 shows a representative experiment and Fig 9 summarises data from two separate experiments performed in quadruplicate. Pre- incubation of neutrophils with EGTA or monoclonal antibodies against E-selectin blocked adhesion of neutrophils.
  • the substances mentioned above should block the interaction of E-selectin with it's ligand and should not have any effect on cytokine induced up-regulation of adhesion molecules.
  • a cell-ELISA was performed to assess the surface expression of adhesion molecules.
  • Endothelial cells were grown in microtiter plates, stimulated with TNF or IL-1 with or without respective substances for 4 h at 37°C. After stimulation the cells were washed and fixed with formaldehyde. A cell-ELISA was performed in analogy to regular ELISA using primary and secondary antibodies.
  • E-selectin transfected L-cells were incubated with 1 mM, 0.1 mM, 0.001 m-M, 0.1 ⁇ M uridine, thiouridine, or isomaltitol for 2 hours. Viability after incubation was > 90 %. Similarly neutrophils were incubated with 1 mM, 0.1 mM, 0.001 mM, 0.1 ⁇ M uridine, thiouridine, or isomaltitol for 2 hours. Viability after incubation was 80-97%.
  • Uridine, isomaltitol and 4-thiouridine do not affect myeloperoxidase activity. Since the number of adherent neutrophils are calculated by measuring neutrophil myeloperoxidase activity, it could be argued that these substances could have a direct effect on myeloperoxidase activity and thus create a methodological artifact. Neutrophils were incubated with different concentrations of uridine, isomaltitol, and 4-thiouridine (100 ⁇ M, 10 ⁇ M, 1 ⁇ M, 100 nM, 10 nM) for 2 hours at 37°C. Incubation of neutrophils with the substance did not affect absorbance due to myeloperoxidase activity.
  • L-cells and neutrophils were preincubated with decreasing concentrations of maltose, fucose, and thymidine (1 mM, 10 ⁇ M, 0.1 ⁇ M, and 1 nM) for 45 min at 37°C.
  • Neutrophils were then allowed to adhere to L-cells in the presence of respective substances for 20 min at 37°C.
  • Non-adherent cells were removed by repeated washings and the number of adherent cells determined by measuring myeloperoxidase content. Maltose, fucose, and thymidine did not affect the adhesion of neutrophils to E-selectin transfected fibroblasts.
  • L-cells were grown in 96-well microtiter plates. L-cells and neutrophils were preincubated with decreasing concentrations of EGTA (10 mM, 1 mM, 0.1 mM, 10 ⁇ M) for 45 min at 37°C. Neutrophils were then allowed to adhere to L-cells in the presence of EGTA for 20 min at 37°C. Non-adherent cells were removed by repeated washings and the number of adherent cells was determined by measuring myeloperoxidase content. It was observed a dose dependent inhibition of neutrophils adhesion to L-cells. Similarly a dose dependent inhibition of neutrophils adhesion to activated HUVEC was observed.
  • Major inflammatory conditions where the present compounds find use is in asthmatic conditions, Crohn's disease, ulcerous colitis, reperfusion injury, auto-immune diseases, mflammary bowl disease (IBD), arteriosclerosis, restenosis, cancer, coronary heart disease, diabetes, cancer metastasis, rheumatoidal diseases, dermatological diseases, such as psonasis, seborrhea, burn injury, graft rejection
  • compositions normally exist as tablets, granules, capsules (soft or hard), or powders, either coated or uncoated products
  • coated products they may be merely ente ⁇ c coated to provide for a more readily administered preparation, or as a sustained release coated composition, where the release of active compound will take place due to the dissolution of the coating, which dissolution is dependent on where in the gastro-intestmal tract one will have a release
  • the release can be controlled as to place and time
  • Tablets and capsules normally contain one dose of the active compound, I e , the dose determined to fulfill the requirements of obtaining a therapeutically active level in serum or otherwise, either this is required once, twice or more times a day (24 hrs)
  • Rectal compositions are normally prepared as supposito ⁇ es, where the active compound is dissolved or dispersed m a waxy compound or fat having a melting temperature in the range of the body temperature, as to release the active compound when administered rectally
  • Preparations for injection are commonly made for subcutaneous, intramuscular, intravenous, or intra pe ⁇ toneal administration
  • Injection solutions are normally provided with an adjuvant to facilitate absorption of the active compound
  • Preparations for inhalation are commonly present as powders which are administered either in pressu ⁇ zed containers with a dosmg nozzle, or in an inhaler system where the powder is dosed in the system and then the patient is inhaling air through the apparatus to such degree that the powder becomes airborne and enters the respiratory tract, including the lungs
  • Inhalation preparation are normally used for inflammatory conditions m the respiratory tract including the lungs
  • the compositions contain 0.5 to 99 % by weight of active compound, and the remainder is different inert, non-therapeutically active compounds which facilitate administration, preparation such as granulation, tableting, or storage. Such inert materials may, however, have a administratively positive effect.
  • the active compounds of the invention are administered in an amount of 1 to 100 mg per kilogram body weight depending on the condition of the patient, route of administration, age and body weight of the patient, and other considerations made by the physician.
  • the most important aspect hereby is the serum concentration which may be 0.1 to 100 mM of active compounds, in accordance with the present findings.
  • FIG. 1 to 3 Adhesion of granulocytes to E-selectin transfected L-cells incubated with different concentrations of uridine, isomaltitol, and 4-thiouridine, respectively.
  • FIG. 4 to 6 Adhesion of Colo 201 to E-selectin transfected L-cells incubated with different concentrations of uridine, isomaltitol, and 4-thiouridine, respectively.
  • FIG. 7 to 9 Adhesion of granulocytes to TNF stimulated HUNEC co-incubated with different concentrations of isomaltitol, 4-thiouridine, and uridine, respectively
  • FIG. 10 Expression of E-selectin on stimulated HUNEC co-incubated with different concentrations of 4-thiouridine.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne l'utilisation de l'un au moins des composés du groupe constitué des 4-thiouridine, isomaltitol, et uridine pour la préparation de compositions thérapeutiquement actives contre les inflammations aiguës ou chroniques, et/ou les difficultés d'hémostase en relation avec la fonction plaquettaire. L'invention concerne également le traitement des inflammations aiguës ou chroniques, et/ou des difficultés d'hémostase en relation avec la fonction plaquettaire à l'exception de l'utilisation de l'uridine dans le traitement des états inflammatoires imputables à une infection bactérienne.
PCT/SE2000/000827 1999-05-05 2000-05-02 Inhibiteurs specifiques nouveaux agissant contre l'inflammation aiguë ou chronique WO2000067759A1 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU52592/00A AU776520B2 (en) 1999-05-05 2000-05-02 Novel, specific inhibitors of acute and chronic inflammation
EP00937418A EP1181021B1 (fr) 1999-05-05 2000-05-02 Utilisation de 4-thiouridine ou isomaltitol pour le traitement d'inflammations et/ou de l'hémostase
BR0010283-0A BR0010283A (pt) 1999-05-05 2000-05-02 Novos inibidores especìficos de inflamação aguda e crÈnica
JP2000616785A JP2002544165A (ja) 1999-05-05 2000-05-02 急性及び慢性炎症の新規な特異的抑制剤
DE60035583T DE60035583T2 (de) 1999-05-05 2000-05-02 Verwendung von 4-Thiouridin oder Isomaltitol zur Behandlung von Entzündungen und/oder Hämostasis
CA002373052A CA2373052A1 (fr) 1999-05-05 2000-05-02 Inhibiteurs specifiques nouveaux agissant contre l'inflammation aigue ou chronique
US09/986,522 US20020061863A1 (en) 1999-05-05 2001-11-02 Novel, specific inhibitors of acute and chronic inflammation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9901615A SE521031C2 (sv) 1999-05-05 1999-05-05 Nya specifika inhibitorer av akut och kronisk inflammation
SE9901615-6 1999-05-05

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/986,522 Continuation US20020061863A1 (en) 1999-05-05 2001-11-02 Novel, specific inhibitors of acute and chronic inflammation

Publications (1)

Publication Number Publication Date
WO2000067759A1 true WO2000067759A1 (fr) 2000-11-16

Family

ID=20415466

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE2000/000827 WO2000067759A1 (fr) 1999-05-05 2000-05-02 Inhibiteurs specifiques nouveaux agissant contre l'inflammation aiguë ou chronique

Country Status (10)

Country Link
US (2) US20020061863A1 (fr)
EP (2) EP1181021B1 (fr)
JP (1) JP2002544165A (fr)
AT (1) ATE367164T1 (fr)
AU (1) AU776520B2 (fr)
BR (1) BR0010283A (fr)
CA (1) CA2373052A1 (fr)
DE (1) DE60035583T2 (fr)
SE (1) SE521031C2 (fr)
WO (1) WO2000067759A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073359A1 (fr) * 2005-01-03 2006-07-13 Selectica Pharmaceuticals Ab Compositions topiques comprenant de la 44-thiouridine et/ou de l'isomaltitol et/ou de l'uridine
WO2009060186A1 (fr) * 2007-11-05 2009-05-14 Asklepuis Limited Précurseurs sulfonés de la thymidine pour le traitement des hyperplasies épithéliales

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019112383A1 (fr) * 2017-12-08 2019-06-13 윤주석 Diaminate minéral métallique et procédé de préparation associé
CN114469981A (zh) * 2021-12-16 2022-05-13 中国科学院动物研究所 尿苷在促进组织器官再生或治疗和/或预防和/或缓解和/或改善组织器官损伤中的应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462075A2 (fr) * 1990-06-13 1991-12-18 POLIFARMA S.p.A. Utilisation de l'uridine pour le traitement pharmacologique des complications périphériques du diabète
WO1994013687A1 (fr) * 1992-12-08 1994-06-23 Pro-Neuron, Inc. Precurseurs de nucleotides de pyrimidine utilises pour le traitement d'inflammations systemiques et de l'hepatite inflammatoire
WO1996001115A1 (fr) * 1994-07-01 1996-01-18 Pro-Neuron, Inc. Precurseurs de nucleotides de pyrimidine, servant dans le traitement des inflammations systemiques et de l'hepatite inflammatoire

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2307251C2 (de) * 1973-02-14 1984-03-29 Süddeutsche Zucker AG, 6800 Mannheim Arzneimittel zur Behandlung von chronischer Obstipation und Leberschäden
DE2217628C2 (de) * 1972-04-12 1974-06-06 Sueddeutsche Zucker Ag Verfahren zur Herstellung von alpha-D-Glucopyranosido eckige Klammer auf 1-6 eckige Klammer zu sorbit (Isomaltit)
US5470838A (en) * 1987-10-28 1995-11-28 Pro-Neuron, Inc. Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US7173017B1 (en) * 1987-10-28 2007-02-06 Wellstat Therapeutics Corporation Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
EP0339075B1 (fr) 1987-10-28 1993-08-18 Pro-Neuron, Inc. Uridine et cytidine acylees et leurs utilisations
US6329350B1 (en) * 1987-10-28 2001-12-11 Pro-Neuron, Inc. Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
MX9203459A (es) * 1988-11-15 1992-08-01 Merrell Pharma Inc Nuevos derivados de 2'-halometilideno, 2'-etenilideno y 2'-etinilcitidina, uridina y guanosina.
US5607925A (en) * 1988-11-15 1997-03-04 Merrell Pharmaceuticals Inc. Treatment of carcinoma by administration of 2'-halomethylidenyl-2'-deoxynucleosides
JP2529605B2 (ja) 1989-10-23 1996-08-28 株式会社大塚製薬工場 免疫賦活剤
EP1298203A3 (fr) * 1991-08-02 2004-01-21 FAUSTMAN, Denise L. Diagnostic et traitement de maladies auto-immunes
US5229415A (en) 1992-03-24 1993-07-20 Merck & Co., Inc. Alkylthio alkyl avermectins are active antiparasitic agents
US5646182A (en) * 1992-06-15 1997-07-08 Burzynski; Stanislaw R. Methods for treating autoimmune diseases
JP3459013B2 (ja) * 1993-05-19 2003-10-20 株式會社緑十字 ウリジンを有效成分とする關節炎治療剤
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
US5852000A (en) * 1993-08-25 1998-12-22 Otsuka Pharmaceutical Factory, Inc. Cardiac rehabilitation agent
US5753625A (en) * 1995-05-12 1998-05-19 Sangstat Medical Corporation Treatment for inhibiting the progression of autoimmune disease
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
SE9701219D0 (sv) * 1997-04-04 1997-04-04 Astra Pharma Prod New compounds
EP1019725A2 (fr) * 1997-07-22 2000-07-19 Novimmune Sa Methodes diagnostiques et therapeutiques d'une maladie auto-immune telle que le diabete sucre insulinodependant mettant en oeuvre des superantigenes retroviraux
US20020006913A1 (en) * 1997-11-04 2002-01-17 Von Borstel Reid W. Antimutagenic compositions for treatment and prevention of photodamage to skin
US6673606B1 (en) * 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0462075A2 (fr) * 1990-06-13 1991-12-18 POLIFARMA S.p.A. Utilisation de l'uridine pour le traitement pharmacologique des complications périphériques du diabète
WO1994013687A1 (fr) * 1992-12-08 1994-06-23 Pro-Neuron, Inc. Precurseurs de nucleotides de pyrimidine utilises pour le traitement d'inflammations systemiques et de l'hepatite inflammatoire
WO1996001115A1 (fr) * 1994-07-01 1996-01-18 Pro-Neuron, Inc. Precurseurs de nucleotides de pyrimidine, servant dans le traitement des inflammations systemiques et de l'hepatite inflammatoire

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006073359A1 (fr) * 2005-01-03 2006-07-13 Selectica Pharmaceuticals Ab Compositions topiques comprenant de la 44-thiouridine et/ou de l'isomaltitol et/ou de l'uridine
WO2009060186A1 (fr) * 2007-11-05 2009-05-14 Asklepuis Limited Précurseurs sulfonés de la thymidine pour le traitement des hyperplasies épithéliales
US8410125B2 (en) 2007-11-05 2013-04-02 Yagna Limited Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias
AU2008324033B2 (en) * 2007-11-05 2014-01-09 Humanitarian Scientific Llc Sulfonated precursors of thymidine for the treatment of epithelial hyperplasias

Also Published As

Publication number Publication date
EP1790348A3 (fr) 2007-06-13
CA2373052A1 (fr) 2000-11-16
SE9901615L (sv) 2000-12-15
BR0010283A (pt) 2003-07-29
ATE367164T1 (de) 2007-08-15
AU776520B2 (en) 2004-09-16
DE60035583T2 (de) 2008-04-17
DE60035583D1 (de) 2007-08-30
AU5259200A (en) 2000-11-21
EP1181021A1 (fr) 2002-02-27
US20020061863A1 (en) 2002-05-23
SE521031C2 (sv) 2003-09-23
US20050090467A1 (en) 2005-04-28
SE9901615D0 (sv) 1999-05-05
EP1790348A2 (fr) 2007-05-30
EP1181021B1 (fr) 2007-07-18
JP2002544165A (ja) 2002-12-24
US7687476B2 (en) 2010-03-30

Similar Documents

Publication Publication Date Title
JP5829948B2 (ja) 腫瘍を治療する方法
Krishan et al. Cytofluorometric studies on the action of podophyllotoxin and epipodophyllotoxins (VM-26, VP-16-213) on the cell cycle traverse of human lymphoblasts.
Lancet et al. Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy
RU2456983C2 (ru) Комбинация ингибиторов iap и flt3
Yao et al. Transport of the antiviral nucleoside analogs 3'-azido-3'-deoxythymidine and 2', 3'-dideoxycytidine by a recombinant nucleoside transporter (rCNT) expressed in Xenopus laevis oocytes.
Nimmanapalli et al. Arsenic trioxide inhibits translation of mRNA of bcr-abl, resulting in attenuation of Bcr-Abl levels and apoptosis of human leukemia cells
PL199014B1 (pl) Przeciwciało monoklonalne specyficznie wiążące się do integryny αvß6, hybrydoma je wytwarzająca oraz zastosowanie przeciwciała
US20060135529A1 (en) Pharmaceutical compositions comprising thieno[2,3-c]pyridine derivatives and use thereof
US6515001B2 (en) IL-8 receptor ligands-drugs for inflammatory and autoimmune diseases
EP1181021B1 (fr) Utilisation de 4-thiouridine ou isomaltitol pour le traitement d'inflammations et/ou de l'hémostase
ZA200206582B (en) Method for identifying and using A2B adenosine receptor antagonists to mediate mammalian cell proliferation.
AU2017221268B2 (en) Methods comprising fixed intermittent dosing of cediranib
CA2044328A1 (fr) Efomycines a.e et g utilisees comme agents anti-inflammatoires
CA3090376A1 (fr) Inhibiteurs de la kinase complexe d'activation transcriptionnelle notch ("nack") et leurs procedes d'utilisation
Yamaguchi et al. Dexamethasone inhibits basophil migration
CN101588801B (zh) Iap抑制剂和flt3抑制剂的组合
Shirbhate et al. The role of cytokines in activation of tumour-promoting pathways and emergence of cancer drug resistance
Kikuchi et al. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diamminedichloroplatinum (II)
Labro et al. Accumulation of azithromycin and roxithromycin in tracheal epithelial fetal cell lines expressing wild type or mutated cystic fibrosis transmembrane conductance regulator protein (CFTR)
KR101293350B1 (ko) 호중구증다 억제제
Funakoshi et al. Growth inhibition of human pancreatic cancer cells by cholecystokinin receptor antagonist in tissue culture and in nude mice
Lancet et al. Farnesyltransferase inhibitors in hematologic malignancies: new horizons
US20080159983A1 (en) Interleukin-15 antagonists for the treatment of anemia
Barry Calcium Antagonism by Sodium Salicylate: Role in Blood Clotting IN VITRO

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2373052

Country of ref document: CA

Kind code of ref document: A

Ref document number: 2373052

WWE Wipo information: entry into national phase

Ref document number: 2000937418

Country of ref document: EP

Ref document number: 09986522

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2000 616785

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 52592/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000937418

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWG Wipo information: grant in national office

Ref document number: 52592/00

Country of ref document: AU

WWG Wipo information: grant in national office

Ref document number: 2000937418

Country of ref document: EP